Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations

[1]  L. Klimek,et al.  SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups , 2018, Allergo Journal International.

[2]  L. Klimek,et al.  Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases , 2018, Allergo Journal International.

[3]  C. Bachert,et al.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial , 2018, Allergy.

[4]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[5]  Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy , 2018, Allergy.

[6]  R. Wood,et al.  The use of omalizumab in allergen immunotherapy , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  R. Gerth van Wijk,et al.  Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 , 2018, The Journal of allergy and clinical immunology.

[8]  P. Demoly,et al.  Perspectives in allergen immunotherapy: 2017 and beyond , 2018, Allergy.

[9]  M. Türk,et al.  Combination of omalizumab and bee venom immunotherapy: does it work? , 2018, Asia Pacific allergy.

[10]  R. Mösges,et al.  A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy , 2017, Allergy.

[11]  E. Oppel,et al.  Overcoming severe adverse reactions to venom immunotherapy using anti‐IgE antibodies in combination with a high maintenance dose , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  A. Chaker,et al.  [Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment]. , 2017, HNO.

[13]  A. Chaker,et al.  Kosten allergischer Erkrankungen und Einsparpotenziale durch die allergenspezifische Immuntherapie , 2017, HNO.

[14]  U. Rabe,et al.  Long-term efficacy of specific subcutaneous, short-term MPL adjuvant immunotherapy over three treatment and three follow-up years, as measured by quality of life , 2017, Allergo Journal International.

[15]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[16]  J. Bousquet,et al.  Allergen immunotherapy in allergic rhinitis: current use and future trends , 2017, Expert review of clinical immunology.

[17]  L. Klimek,et al.  Clinical use of adjuvants in allergen-immunotherapy , 2017, Expert review of clinical immunology.

[18]  T. Reinhold,et al.  Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment , 2016, Allergo Journal International.

[19]  E. Boni,et al.  Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab , 2016, Clinical and Molecular Allergy.

[20]  L. Ricciardi,et al.  Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy , 2016, International journal of immunopathology and pharmacology.

[21]  M. Larché,et al.  Concepts and perspectives on peptide-based immunotherapy in allergy , 2016, Allergo Journal International.

[22]  R. Valenta,et al.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy , 2016, EBioMedicine.

[23]  F. Spertini,et al.  Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. , 2016, The Journal of allergy and clinical immunology.

[24]  J. Virchow,et al.  Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. , 2016, JAMA.

[25]  A. Henning,et al.  A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. , 2016, The Journal of allergy and clinical immunology.

[26]  L. Klimek,et al.  Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany , 2016, Allergo Journal International.

[27]  S. Durham,et al.  Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. , 2016, The Journal of allergy and clinical immunology.

[28]  A. Distler,et al.  13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation , 2015, Allergo Journal International.

[29]  S. Hewings,et al.  The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy. , 2015, Journal of inorganic biochemistry.

[30]  Y. Shoenfeld,et al.  Vaccines, adjuvants and autoimmunity , 2015, Pharmacological Research.

[31]  A. Nandy,et al.  Recombinant allergens in specific immunotherapy , 2015, Allergo Journal International.

[32]  R. Valenta,et al.  Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy , 2015, The Journal of allergy and clinical immunology.

[33]  E. Jensen‐Jarolim.  Aluminium in Allergies and Allergen immunotherapy , 2015, The World Allergy Organization journal.

[34]  H. Sitter,et al.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases , 2014, Allergo Journal International.

[35]  L. Klimek,et al.  Is The Allergen Really Needed in Allergy Immunotherapy? , 2014, Current Treatment Options in Allergy.

[36]  R. Valenta,et al.  Preventive sublingual immunotherapy in preschool children: First evidence for safety and pro‐tolerogenic effects , 2014, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[37]  B. Wedi,et al.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab]. , 2014, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[38]  A. Kapp,et al.  Unverträglichkeit der spezifischen Immuntherapie mit Hymenopterengift , 2014, Der Hautarzt.

[39]  M. Kramer,et al.  Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective. , 2014, Vaccine.

[40]  T. Casale,et al.  Immunotherapy: what lies beyond. , 2014, The Journal of allergy and clinical immunology.

[41]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.

[42]  D. Larenas-Linnemann,et al.  Use of omalizumab to improve desensitization safety in allergen immunotherapy. , 2014, The Journal of allergy and clinical immunology.

[43]  C. Corrigan,et al.  Adjuvants in Allergy: State of the Art , 2014, Current Treatment Options in Allergy.

[44]  E. Blood,et al.  Food , drug , insect sting allergy , and anaphylaxis A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients , 2013 .

[45]  L. Klimek,et al.  [Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs]. , 2013, HNO.

[46]  L. Klimek,et al.  [Specific immunotherapy : clinical experience with recombinant molecular major allergens and hypoallergenic variants]. , 2013, HNO.

[47]  L. Klimek,et al.  Immuntherapie der allergischen Rhinitis ohne Allergene? , 2013, HNO.

[48]  F. Spertini,et al.  Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides , 2013, Clinical and Translational Allergy.

[49]  L. Klimek,et al.  Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs , 2013, American journal of rhinology & allergy.

[50]  T. Casale,et al.  Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.

[51]  D. Larenas-Linnemann,et al.  Adjuvants for immunotherapy , 2012, Current opinion in allergy and clinical immunology.

[52]  P. Moingeon.  Adjuvants for allergy vaccines , 2012, Human vaccines & immunotherapeutics.

[53]  L. Klimek,et al.  Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  C. Mandl,et al.  Vaccines for the twenty-first century society , 2011, Nature Reviews Immunology.

[55]  P. Keith,et al.  Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. , 2011, Allergy and asthma proceedings.

[56]  O. Pfaar,et al.  Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[57]  Rudolf Valenta,et al.  Recombinant allergens for allergen‐specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens , 2011, Allergy.

[58]  K. Nadeau,et al.  Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. , 2011, The Journal of allergy and clinical immunology.

[59]  O. Cromwell,et al.  Recombinant allergens for specific immunotherapy. , 2011, The Journal of allergy and clinical immunology.

[60]  P. Kardos,et al.  Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. , 2010, The Journal of allergy and clinical immunology.

[61]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[62]  R. Dummer,et al.  Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients , 2010, Journal of immunotherapy.

[63]  R. Puy,et al.  Injection allergen immunotherapy for asthma. , 2010, The Cochrane database of systematic reviews.

[64]  C. Chu,et al.  Synthesis, characterization and biodegradation of functionalized amino acid-based poly(ester amide)s. , 2010, Biomaterials.

[65]  W. Busse,et al.  Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. , 2010, The Journal of allergy and clinical immunology.

[66]  Hyunjin Shin,et al.  TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients1 , 2009, The Journal of Immunology.

[67]  T. Kündig,et al.  Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[68]  K. Bergmann,et al.  Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  H. Malling,et al.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. , 2008, The Journal of allergy and clinical immunology.

[70]  Rino Rappuoli,et al.  Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.

[71]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[72]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[73]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[74]  J. Kline.  Eat dirt: CpG DNA and immunomodulation of asthma. , 2007, Proceedings of the American Thoracic Society.

[75]  H. HogenEsch,et al.  Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. , 2007, Vaccine.

[76]  R. Valenta,et al.  Recombinant allergens for immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[77]  R. Coffman,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[78]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[79]  M. Larché,et al.  Immunotherapy with peptides , 2011, Allergy.

[80]  T. Kündig,et al.  Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. , 2006, The Journal of allergy and clinical immunology.

[81]  H. Fiebig,et al.  Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. , 2006, Immunology and allergy clinics of North America.

[82]  R. Coffman,et al.  Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction , 2005, The Journal of experimental medicine.

[83]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[84]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[85]  Y. Li,et al.  Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. , 2004, Vaccine.

[86]  R. Valenta,et al.  Vaccine Engineering Improved by Hybrid Technology , 2004, International Archives of Allergy and Immunology.

[87]  H. Matsue,et al.  TLR3-, TLR7-, and TLR9-Mediated Production of Proinflammatory Cytokines and Chemokines from Murine Connective Tissue Type Skin-Derived Mast Cells but Not from Bone Marrow-Derived Mast Cells 1 , 2004, The Journal of Immunology.

[88]  H. Fiebig,et al.  Transition of recombinant allergens from bench to clinical application. , 2004, Methods.

[89]  R. Valenta,et al.  Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[90]  A. Wheeler,et al.  Review of L‐tyrosine confirming its safe human use as an adjuvant , 2002, Journal of applied toxicology : JAT.

[91]  H. Breiteneder,et al.  Genetic Engineering of Allergens: Future Therapeutic Products , 2002, International Archives of Allergy and Immunology.

[92]  P. Eng,et al.  Long‐term efficacy of preseasonal grass pollen immunotherapy in children , 2002, Allergy.

[93]  K. Bergmann,et al.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. , 2002, The Journal of allergy and clinical immunology.

[94]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[95]  A. Wheeler,et al.  A Th1-Inducing Adjuvant, MPL®, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines , 2001, International Archives of Allergy and Immunology.

[96]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[97]  R. Merendino,et al.  Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[98]  A. Kagey‐Sobotka,et al.  Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. , 2001, The Journal of allergy and clinical immunology.

[99]  C. Traube,et al.  Immunotherapy with a calcium phosphate‐adsorbed five‐grass‐pollen extract in seasonal rhinoconjunctivitis: a double‐blind, placebo‐controlled study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[100]  F. Horak,et al.  A well‐tolerated grass pollen‐specific allergy vaccine containing
a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.

[101]  M. Ulanova,et al.  The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism , 2001, Infection and Immunity.

[102]  E. Raz,et al.  Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. , 2000, The Journal of allergy and clinical immunology.

[103]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. , 1997, The Journal of allergy and clinical immunology.

[104]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[105]  H. Bluethmann,et al.  In interleukin‐4‐deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production , 1996, European journal of immunology.

[106]  M. Kapsenberg,et al.  Relationship between facilitated allergen presentation and the presence of allergen‐specific IgE in serum of atopic patients , 1995, Clinical and experimental immunology.

[107]  M. Larché,et al.  Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. , 2013, The Journal of allergy and clinical immunology.

[108]  L. Klimek,et al.  Spezifische Immuntherapie , 2013, HNO.

[109]  A. Burks,et al.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. , 2011, The Journal of allergy and clinical immunology.

[110]  M. Worm,et al.  Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. , 2011, The Journal of allergy and clinical immunology.

[111]  Vicki Seyfert-Margolis,et al.  Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[112]  A. Wheeler,et al.  Immunological adjuvants in allergy vaccines: Past, present and future , 2001 .

[113]  J. T. Ulrich,et al.  Monophosphoryl Lipid A as an Adjuvant , 1995 .

[114]  A. Wheeler,et al.  l-Tyrosine as an immunological adjuvant. , 1982, International archives of allergy and applied immunology.